Wonmet G1 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 1000mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The prolonged-release formulation of Wonmet G1 Forte ensures a sustained therapeutic effect, promoting better patient compliance through once-daily dosing. This combination is indicated for patients whose blood glucose levels are inadequately controlled by diet and exercise alone or when monotherapy with either agent is insufficient. It is essential to monitor renal function prior to and during therapy, as Metformin is contraindicated in patients with significant renal impairment due to the risk of lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, which often subside with continued use. Hypoglycemia is a potential risk primarily associated with Glimepiride. Dose adjustments and careful monitoring are advised in elderly patients and those with hepatic dysfunction. Wonmet G1 Forte should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring.